REGENXBIO (NASDAQ:RGNX) Stock Rating Lowered by StockNews.com

REGENXBIO (NASDAQ:RGNX - Get Free Report) was downgraded by StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Saturday.

A number of other research firms also recently issued reports on RGNX. Raymond James initiated coverage on shares of REGENXBIO in a report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price objective on the stock. Chardan Capital reissued a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Wednesday, November 20th. Morgan Stanley reaffirmed an "overweight" rating and issued a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. Royal Bank of Canada reissued an "outperform" rating and set a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of REGENXBIO in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $33.45.

REGENXBIO Trading Up 4.7 %

RGNX stock traded up $0.34 during trading on Friday, reaching $7.64. The stock had a trading volume of 196,795 shares, compared to its average volume of 976,194. The firm has a market cap of $378.49 million, a PE ratio of -1.52 and a beta of 1.29. The stock's 50 day moving average is $7.83 and its two-hundred day moving average is $9.74. REGENXBIO has a 52 week low of $6.56 and a 52 week high of $28.80.

Institutional Investors Weigh In On REGENXBIO

Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in shares of REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after acquiring an additional 2,510 shares during the last quarter. FMR LLC boosted its holdings in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,656 shares during the last quarter. nVerses Capital LLC grew its position in shares of REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 2,200 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of REGENXBIO during the fourth quarter valued at about $54,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of REGENXBIO in the fourth quarter worth about $79,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.